Detalhe da pesquisa
1.
Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
J Clin Rheumatol
; 25(3): 115-126, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29794874
2.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Lancet
; 390(10093): 457-468, 2017 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28629665
3.
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Ann Rheum Dis
; 75(7): 1293-301, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26275429
4.
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Ann Rheum Dis
; 75(5): 831-41, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25902789
5.
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Ann Rheum Dis
; 75(6): 1024-33, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27002108
6.
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
Ann Rheum Dis
; 75(4): 687-95, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25795907
7.
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib.
Ann Rheum Dis
; 79(5): 669-671, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32161057
8.
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Lancet
; 381(9865): 451-60, 2013 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-23294500
9.
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development.
Drug Discov Today
; 29(5): 103948, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38460567
10.
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
Arthritis Res Ther
; 23(1): 220, 2021 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34429160
11.
Demographic diversity of participants in Pfizer sponsored clinical trials in the United States.
Contemp Clin Trials
; 106: 106421, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33940253
12.
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Clin Rheumatol
; 39(7): 2127-2137, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32048083
13.
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Arthritis Care Res (Hoboken)
; 72(3): 353-359, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31207152
14.
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Arthritis Rheumatol
; 71(9): 1450-1459, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31385441
15.
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
RMD Open
; 5(2): e001040, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31673419
16.
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Arthritis Res Ther
; 21(1): 89, 2019 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30953540
17.
Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
Rheumatol Ther
; 5(2): 383-401, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29949132
18.
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
Arthritis Rheumatol
; 69(10): 1969-1977, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28845577
19.
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Semin Arthritis Rheum
; 46(3): 261-271, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27443588
20.
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Arthritis Rheumatol
; 66(11): 2924-37, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25047021